.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Accenture
McKinsey
Colorcon
Federal Trade Commission
Dow
Baxter
Healthtrust
Queensland Health

Generated: December 18, 2017

DrugPatentWatch Database Preview

VELOSEF Drug Profile

« Back to Dashboard

When do Velosef patents expire, and when can generic versions of Velosef launch?

Velosef is a drug marketed by Apothecon, Bristol Myers Squibb, and Ersana. and is included in five NDAs.

The generic ingredient in VELOSEF is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
Drug patent expirations by year for VELOSEF

Medical Subject Heading (MeSH) Categories for VELOSEF

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
ApotheconVELOSEFcephradineCAPSULE;ORAL061764-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ApotheconVELOSEFcephradineINJECTABLE;INJECTION061976-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ApotheconVELOSEFcephradineINJECTABLE;INJECTION061976-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ErsanaVELOSEF '500'cephradineCAPSULE;ORAL050548-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbVELOSEFcephradineTABLET;ORAL050530-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ApotheconVELOSEFcephradineCAPSULE;ORAL061764-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ApotheconVELOSEFcephradineINJECTABLE;INJECTION061976-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ApotheconVELOSEFcephradineINJECTABLE;INJECTION061976-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ApotheconVELOSEFcephradineINJECTABLE;INJECTION061976-005Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
ErsanaVELOSEF '250'cephradineCAPSULE;ORAL050548-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Accenture
Queensland Health
Moodys
US Army
Federal Trade Commission
Novartis
Johnson and Johnson
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot